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!What is Evolution? Bicentennial of Charles Darwin's BirthJ 
This switch also would bring diversity to some extent because useful mutations 
could be introduced. Needless to say, diploidization connotes fertilization, and 
haplodization connotes meiosis. 
I also stress that this alternation cycle can easily accept the advanced form of 
sexual reproduction beginning with the haploid cell fusion. Because the genomic 
duplication (Du) is equivalent to the genomic cell fusion (Fu) as for diploidization, 
one of the Du-Di modules of the haploid cell cycle is easily replaced with a Fu-Di 
motif: it is nothing but the one-step meiosis. If a transition from diploid to haploid 
occurs in such the way of Fu-Du-Di-Di- instead of Du-Di-Di-, it is nothing but the 
two-step meiosis. 
Taken altogether, the alternation of asexual cycles between diploid and 
haploid is considered the primitive form of sexual reproduction. 
Oct. 16 (Fri.) 15:40-16:20 
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Cancers result from the accumulation of inherited and somatic mutations in 
oncogenes and tumor suppressor genes. Those mutations increase the net 
reproductive rate of cells. Many aspects of carcinogenesis can be handled as 
evolutionary processes. 
[1] Chromosomal instability (CIN) is a feature of most human cancers. From 
the mathematical analysis of situations where inactivation of one or two tumor 
suppressor genes is required for tumorigenesis, we conclude that CIN is likely to 
emerge first and then enhance the risk of cancer. 
[2] Most epithelial tissues have common architecture --a tissue is organized 
into numerous small compartments, and within each compartment includes a 
few stem cells and numerous differentiated cells. This design can slow down 
delay the onset of cancer. 
[3] The ABL tyrosine kinase inhibitor imatinib in chronic myeloid leukemia 
(CML) serves as a model for molecularly targeted therapy of cancer. We show 
that a four-compartment model can explain the kinetics of the molecular 
response to imatinib in a 169-patient data set. We also calculate the probability 
of developing imatinib resistance mutations. 
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